Send E-mail
  • Kolon Life Science seeks approval to market gene therapy for degenerative arthritis
    Kolon Life Science seeks approval to market gene therapy for degenerative arthritis
    Kolon Life Science (102940) announced on July 11 that it has filed for approval from the Ministry of Food and Drug Safety to market Invossa, a treatment for osteoarthritis. 　Developed under the name Tissuegene-C, it is the first gene therapy to seek approval in Korea, and the first allogeneic cell therapy in the world. Invossa treats degenerative arthritis by injecting genetically modified cartilage cells and allev...
From
Send to
Close Send

Kolon Life Science seeks approval to market gene therapy for degenerative arthritis

July 11, 2016 - 08:59 By 황유미

[DISCLOSURE] Kolon Life Science (102940) announced on July 11 that it has filed for approval from the Ministry of Food and Drug Safety to market Invossa, a treatment for osteoarthritis.

Developed under the name Tissuegene-C, it is the first gene therapy to seek approval in Korea, and the first allogeneic cell therapy in the world. Invossa treats degenerative arthritis by injecting genetically modified cartilage cells and alleviates pains, slows down degeneration and improves cartilages, the company explained.

Most Popular